Overview

A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

This study is a randomized pilot/pharmacodynamic/genomic study of neoadjuvant paricalcitol to target the microenvironment in resectable pancreatic cancer to determine the effect of targeting the vitamin D metabolic program in the tumors of patients treated with one cycle of gemcitabine/abraxane with or without paricalcitol prior to surgery for resectable pancreatic cancer through an assessment of cellular and imaging markers.

Phase:

N/A

Details

Lead Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Treatments:

Albumin-Bound Paclitaxel
Ergocalciferols
Gemcitabine